In June 2014, Ohio became the 34th state, plus the District of Columbia, to enact a law that requires health insurers to provide coverage for oral chemotherapeutic agents under “no less favorable” terms than for intravenous chemotherapy (Table). Legislators, physicians, and patient advocacy groups have lauded these so-called oral chemotherapy parity laws for making expensive cancer therapies more affordable and accessible to patients. These laws mean well. They are, however, at best an inadequate response to the more fundamental problem of the increasing costs of cancer medications.
Wang B, Joffe S, Kesselheim AS. Chemotherapy Parity Laws: A Remedy for High Drug Costs? JAMA Intern Med. 2014;174(11):1721–1722. doi:10.1001/jamainternmed.2014.4878
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: